$21.56
0.55%
Nasdaq, Sep 29, 11:06 am EDT. Market open.
ISIN
US45257U1088
Symbol
IMNM

Immunome Inc Target price 2026 - Analyst rating & recommendation

Immunome Inc Classifications & Recommendation

Buy
95%
Hold
5%

Immunome Inc Price Target

Target Price $36.72
Price $21.68
Potential
Number of Estimates 15
15 Analysts have issued a price target Immunome Inc 2027 . The average Immunome Inc target price is $36.72. This is higher than the current stock price. The highest price target is , the lowest is .
A rating was issued by 20 analysts: 19 Analysts recommend Immunome Inc to buy, 1 to hold and 0 to sell.
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
Analyst Estimates: Analysts believe that the Immunome Inc stock has an average upside potential 2027 of . Most analysts recommend the Immunome Inc stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 to 2033

Create a premium account to unlock analyst estimates. Learn more

Select at least one metric to display the chart.


Quarter Annually
Dec '25 2026
Estimates
Earnings Per Share $ -2.43 -2.42
51.40% 0.41%
P/E negative
EV/Sales 5,712.88

16 Analysts have issued a Immunome Inc forecast for earnings per share. The average Immunome Inc EPS is

$-2.42
unlock
. This is
8.04% lower
unlock
than earnings per share in the financial year 2025. The highest EPS forecast is
$-2.16 3.57%
unlock
, the lowest is
$-2.51 12.05%
unlock
.

This results in the following potential growth metrics and future valuations:

Earnings Per Share

2025 $-2.43 51.40%
2026
$-2.42 0.41%
unlock
2027
$-2.58 6.61%
unlock
2028
$-1.56 39.53%
unlock
2029
$0.42 126.92%
unlock
2030
$1.62 285.71%
unlock
2031
$2.72 67.90%
unlock
2032
$3.54 30.15%
unlock
2033
$4.59 29.66%
unlock

P/E ratio

Current -9.68 103.76%
2026
-8.95 7.53%
unlock
2027
-8.41 6.03%
unlock
2028
-13.86 64.80%
unlock
2029
51.34 470.42%
unlock
2030
13.42 73.86%
unlock
2031
7.98 40.54%
unlock
2032
6.12 23.31%
unlock
2033
4.72 22.88%
unlock

Current Immunome Inc Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more
Analyst Rating Action Date
Alliance Global Partners
Locked
➜
Locked
Locked Sep 21 2026
HC Wainwright & Co.
Locked
➜
Locked
Locked Sep 10 2026
Wedbush
Locked
➜
Locked
Locked Aug 12 2026
Truist Securities
Locked
➜
Locked
Locked Aug 12 2026
Wedbush
Locked
➜
Locked
Locked Jul 21 2026
Wedbush
Locked
➜
Locked
Locked Jun 12 2026
Barclays
Locked
➜
Locked
Locked May 28 2026
Analyst Rating Date
Locked
Alliance Global Partners:
Locked
➜
Locked
Sep 21 2026
Locked
HC Wainwright & Co.:
Locked
➜
Locked
Sep 10 2026
Locked
Wedbush:
Locked
➜
Locked
Aug 12 2026
Locked
Truist Securities:
Locked
➜
Locked
Aug 12 2026
Locked
Wedbush:
Locked
➜
Locked
Jul 21 2026
Locked
Wedbush:
Locked
➜
Locked
Jun 12 2026
Locked
Barclays:
Locked
➜
Locked
May 28 2026

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today